MTTI
 
ۼ : 12-05-07
[MTTI] For imaging of cell death and bacterial infections
Phosphatidylserine(PS) probe
PSVue for imaging of cell death and bacterial infections
Phosphatidylserine(PS) probeԴϴ.
 
PROPOSED MECHANISM OF BINDING OF PSVue TO APOPTOTIC MEMBRANES: A TWO-POINT INTERACTION
 
PSVue bis(zinc2 + dipicolylamine : Zn-DPA) ϴ fluorescent probes Դϴ. Zn-DPA anionic phospholipids ģȭ Ÿ ˷ , phosphatidylserine(PS) մϴ. apoptotic cells [1], necrotic cells [2], Gram+ and Gram- bacteria [3-5], activated cells, tumor vascular endothelial cells, viruses ⿡ ֽϴ.
 
Key Features of PSVue Probes:
  • Bind to a variety of cell types which have negatively charged phospholipids exposed on their membranes including apoptotic cells [1], necrotic cells [2], Gram+ and Gram- bacteria [3-5], activated cells, tumor vascular endothelial cells, viruses, etc.
  • Available in a range of detection wavelengths from long-UV to near infrared.
  • Suitable for in vitro and in vivo use.
  • Suitable for high-throughput screening assays.
  • Bind to the  same PS site as annexin-V.
 
Advantages of PSVue over Fluorescent Annexin-V:
  • Binding kinetics are fast; annexin-V binding is slow
  • Binding is Ca+ independent; means no artifacts due to activation of nonspecific membrane scramblases by Ca+.
  • Cheap compared to most annexin-V fluorescent analogs
  • Apoptosis can be detected under a wide variety of conditions(e.g. in presence of 10% serum, temps from 4 to 37C).
  • Can provide more intense labeling due to their much smaller size (i.e. >10 PSVueTM molecules can bind to the same area as 1 annexin V molecule).
 
PMicrographs (60X magnification) of Jurkat cells, treated with cytotoxic camptothecin (10 M) for 3.5 h and stained simultaneously with Annexin VAlexa Fluor 488, and PSVue 794 (10 M). Brightfield image of the entire field of cells (A); cells stained with Annexin V-Alexa Fluor 488 (B); cells stained with PSVue 794 (C); overlay of images A, B, and C (D). No staining of healthy cells was observed in the absence of camptothecin. (Image courtesy of Dr. Bradley Smith of University of Notre Dame)
 
 
 
Catalog No.
Name
Description
P-1001
The PSVue794 (formerly PSS-794) reagent kit contains components to provide ~ 0.68 mL of a 1 mM solution of PSVue794 in aqueous solution. The compound exhibits absorbance and fluorescence excitation maximum at 794 nm and emission maximum at 810 nm. The labeling vehicle provided with the kit (Diluent X) is designed to maximize dye solubility and is suitable for in vitro and in vivo use.
P-1002
The PSVue380 (formerly PSS-380) reagent kit contains components to provide ~ 0.40 mL of a 2 mM solution of PSVue380 in 50% aqueous ethanol solution. The compound has an absorbance max at 380nm and a fluorescence emission max at 440nm.
P-1003
The PSVue480 (formerly PSS-480) reagent kit contains components to provide ~0.5 mL of a 1 mM solution of PSVue480 in 50% aqueous dimethylsulfoxide solution. The compound has an absorbance max at 480nm and an fluorescence emission max at 519 nm
P-1004
PSVue Biotin
Vial contains 1mg of solid. PSVue biotin can be complexed with streptavidin-coated quantum dots (not provided) for in vivo and in vitro use. Procedures to formulate PSVuebiotin and prepare the PSVue biotin-streptavidin -coated quantum dot complex are provided.
P-1005
The PSVue550 reagent kit contains components to provide ~0.5 mL of a 1 mM solution of PSVue550. The compound has an absorbance max at 553 nm and an fluorescence emission max at 615 nm
P-1006
The PSVue643 kit contains 0.25mL of a 1mM solution of PSVue643 in water. The compound has an absorbance max at 643nm and a fluorescence emission max at 658nm
P-1007
PSVue 794
This probe contains the same fluorophore present in PSVue 794 but without the Zn-DPA targeting moiety attached. The kit contains 0.6mL of a 1 mM solution of 794-control probe in aqueous solution. The compound exhibits absorbance and fluorescence excitation maximum at 787 nm and emission maximum at 808 nm
 
* PSVue is a trademark of Molecular Targeting Technologies, Inc. PSVue products are sold under an exclusive license from the University of Notre Dame.US Patent # 7,179,616 and others pending.